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agents for various applications in biomed-
ical optics, including the photothermal 
ablation and the photoacoustic imaging 
(PAI)[7,8] of cancer, which are emerging 
as hopeful alternatives in oncology. A 
favorable premise of gold nanoparticles is 
their good tolerability in vivo.[9–11] More-
over, at variance with gold nanospheres 
that resonate in the green as many bio-
logical dyes including hemoglobin, the 
particular shapes of gold nanorods, shells, 
and cages originate new bands of optical 
absorbance in the near infrared (NIR),[12] 
which are ideal to achieve high penetration 
and contrast in biotissue. In particular, 
the plasmonic bands of gold nanorods 
are tunable across the entire window of 
the NIR with their size and shape and pro-
vide for unique cross sections of optical 
absorbance.[5,13–15] Their efficiency of 
photothermal conversion outclasses that 
of organic dyes by several orders of mag-
nitude and also that of alternative gold 
nanoparticles.[16,17] Another advantage over organic dyes is 
the stability of these cross sections in biological fluids. How-
ever, new pitfalls are hidden at the interface with cells.[9] For 
instance, as gold nanoparticles undergo endocytic uptake, their 
aggregation within tight vesicles may jeopardize their optical 
features,[18–20] due to plasmonic coupling. Different authors 
have proposed the use of rigid shells such as silica as a spacer 
to prevent this warning.[19,21] Indeed, floccules of silanized gold 
nanorods in anhydrous biopolymers retain most of their optical 
features, while softer shells such as polyethylene glycol (PEG) 
are ineffective.[18] However, while inorganic shells may provide 
new functions,[22,23] we found a different scenario in endocytic 
vesicles. There, we noted that PEG strands of the appropriate 
weight are enough to inhibit plasmonic coupling.[24] In essence, 
whereas PEG shells collapse in anhydrous environments, 
their steric hindrance works well in moist conditions, even at 
extreme concentrations. In addition, the colloidal stability of 
PEGylated gold nanorods in biological fluids is critical for the 
feasibility of their tests in vitro and in vivo.[25,26]
At present, one of the most relevant challenges in nanomedi-
cine is to really optimize the delivery of functional nanoparticles 
into tumors upon systemic administration, as a magic bullet. In 
this context, PEGylated gold nanorods are a promising platform. 
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The pursuit of more selectivity in the delivery of plasmonic particles to 
tumors is critical before their penetration into clinical applications as the 
photoacoustic imaging and the photothermal ablation of cancer. As their 
direct infusion into the bloodstream remains problematic, due to a multitude 
of biological barriers, the development of alternative approaches is emerging 
as a new challenge. In this context, the recruitment of homologous tumor-
tropic cells that may serve as Trojan horses stands out as a fascinating 
possibility. Here, a novel model of gold nanorods is presented that feature 
a composite shell and undergo efficient and reproducible endocytic uptake 
from murine macrophages, which is fine-tunable over a broad range of 
conditions. These cells preserve their viability and more than 90% of their 
innate chemotactic behavior in vitro, even with a cargo exceeding 200 000 
particles per cell. In addition, we show that these vehicles are detectible by 
photoacoustic imaging down to concentrations in the order of 1% in whole 
blood and by clinical X-ray computed tomography below 10%, which is within 
the typical fraction of a leukocytic infiltrate in a tumor microenvironment, and 
may even work as contrast agents for the photothermal ablation of cancer.
DOI: 10.1002/adfm.201600836
1. Introduction
The clinical exploitation of plasmonic particles such as gold 
nanorods, shells, cages, and other nonspherical shapes has 
become a remarkable mission for a willful community of sci-
entists.[1–6] These particles are being proposed as contrast 
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Their hydrodynamic size is ideal to passively pervade tumors 
that exhibit enhanced vascular permeability and poor lym-
phatic drainage.[10,27–29] Besides, PEG strands and other spacers 
holding reactive moieties enable their bioconjugation with tar-
geting units that actively bind malignant phenotypes.[20,24,30,31] 
PEGylated and bioconjugated gold nanorods display high speci-
ficity and blood compatibility in vitro.[30] Therefore, their direct 
injection into the bloodstream has become a mainstream solu-
tion. However, after more than one decade of preclinical trials 
in dozens of labs, this route still remains problematic. Upon 
intravenous injection, more than ≈90% of the gold nanorods 
typically get captured by the mononuclear phagocyte system 
(MPS).[4,10,32,33] Indeed the complexity of the biological barriers 
in the body,[34] comprising the MPS, the vessel walls, the tumor 
stroma, etc. poses a formidable challenge to really optimize the 
design of these particles.
More recently, the notion to exploit the natural tropism of 
cells, such as tumor-associated macrophages,[35–39] T cells,[40] 
mesenchymal stem cells,[41–43] and neural stem cells,[44,45] has 
begun to emerge as a radical alternative. These cells hold an 
innate ability to detect and to infiltrate tumors with high speci-
ficity,[46–49] with the aim to modulate their microenvironment 
in a variety of ways. In particular, macrophagic infiltrates are 
common in cancer as well as in atherosclerosis, myocardial 
infarction, aortic aneurysm, diabetes, and other conditions and 
are emerging as a new target for imaging and treatments.[50–54] 
In most tumors, the extent of macrophagic infiltrates correlates 
with a poor prognosis and may exceed 50% of their size.[55–57] 
These macrophages accumulate even in hypoxic and necrotic 
segments, stimulate the angiogenesis, support the malignant 
cells in terms of invasion, motility, intravasation in primary sites 
and of extravasation, survival, and persistent growth in metastatic 
sites, prime premetastatic sites, and also play an immunosup-
pressive role, by protecting the malignant cells against natural 
killer and T cells.[47] In turn, tumor-associated macrophages 
may be conceived of as Trojan horses to take up and to deliver 
functional cargos to their biological target, including plasmonic 
particles such as gold nanoshells.[35–39] Several authors have 
suggested that this approach may improve the distribution and 
retention of different particles both in malignant against normal 
tissue[36,40,42] and within malignant tissue.[43–45] Other advantages 
include a full personalization of the treatment and a remarkable 
simplification of the biological interface.
In essence, the design of gold nanorods needs to provide 
for their efficient uptake from macrophagic cells that main-
tain their viability and tropism. Over recent years, Vigderman 
et al.[58] and Schnarr et al.[45] have shown that quaternary ammo-
nium compounds are capable to drive a massive uptake of 
gold nanorods into endocytic vesicles, due to their positive zeta 
potential.[59] Here, we combine this notion with the observation 
that cell penetrating agents with a cationic profile[60,61] preserve 
their functionality after inclusion within PEG shells,[62] which 
add colloidal stability and biocompatibility.[25,26] We propose a 
novel design of polycationic gold nanorods that enable a robust 
fabrication of cellular vehicles. We demonstrate their viability 
and tropism and their use as contrast agents for PAI and X-ray 
computed tomography (CT) even in whole human blood in a 
tissue-like optical phantom down to concentrations of a few per-
cent, which is at least an order of magnitude below the typical 
extent of macrophagic infiltrates in tumors. While previous 
work has demonstrated the use of cellular vehicles for specific 
applications in vivo,[36,40,42–44,46] our primary focus rests on an 
innovative design of plasmonic particles for an efficient inte-
gration into macrophages exhibiting functional optical features 
and maintaining their viability and chemotactic performance.
2. Results and Discussion
2.1. Polycationic Gold Nanorods
As it is discussed in the Experimental Section, gold nanorods 
were PEGylated and then saturated with (11-Mercaptoundecyl)-
N,N,N-trimethylammonium bromide (MUTAB) in one pot, in 
order to achieve polycationic particles. Their zeta potential was 
(20 ± 2) mV, which is attributed to the permanent charge of 
the quaternary ammonium moieties of MUTAB. As a refer-
ence, this value dropped to (−18 ± 2) mV when MUTAB was 
replaced with 11-mercaptoundecanoic acid, which only differs 
from MUTAB by the substitution of the quaternary ammonium 
end with a C-terminus. The zeta potential of polycationic gold 
nanorods from different batches within a range of aspect ratios 
from ≈3.0 to ≈4.5 and effective radii around 10 nm was found 
to differ from each other by less than ±10%. The colloidal sta-
bility of these particles proved to be optimal even after at least 
five cycles of centrifugation and dispersion in phosphate buff-
ered saline (PBS) and various culture media up to gold contents 
around 80 × 10−3 m Au, which is about the PEG shells. We note 
that, when we tried to modify gold nanorods with MUTAB in 
the absence of PEG, as in Schnarr et al.[45] and Mooney et al.[44] 
particles began to flocculate in PBS soon after the first cycle of 
centrifugation, which would be a major concern for the repro-
ducibility of their applications.
2.2. Plasmonic Macrophages: Optical Features
Murine macrophages were incubated with different concen-
trations of polycationic gold nanorods over different times. 
Figure 1 and Figure S1 of the Supporting Information report 
representative images of macrophages treated for 24 h with 
400 × 10−6 m Au. The presence of a dark particulate within the 
perinuclear cytoplasm is already visible by the use of an optical 
microscope, as it is seen in Figure S1 of the Supporting Infor-
mation. On closer inspection by the use of electron microscopy, 
gold nanorods are seen to undergo tight confinement within 
endocytic vesicles that exhibit a broad range of sizes in the 
order of a few hundred nm and distances of a few μm, which is 
consistent with the findings from other authors.[20,45,58,59]
On visual inspection, the pellets of these cells became 
darker and darker both with the increase of incubation dosage 
and time. In an attempt to quantify the underlying kinetics, 
these pellets were fixed, resuspended in PBS and directed to 
an optical analysis. Their spectra of optical extinction revealed 
the same plasmonic bands as the original suspensions of gold 
nanorods, with minimal modifications (see Figure S2, Sup-
porting Information), which implies the absence of significant 
plasmonic coupling. Their lineshapes were modeled as the 
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sum of an empirical background from an unknown number 
of cells, which was calibrated in a preliminary measurement, 
plus a numerical approximation of the plasmonic band from 
an unknown number of gold nanorods. The latter was devised 
as a convolution integral between Gans lineshape,[15,63,64] 
which was implemented with the dielectric function by Etch-
egoin et al.[65] and an unknown distribution of aspect ratios. 
Details and a demonstration of this method are reported else-
where.[24,63,64] The output of this analysis is a number of parti-
cles per cell. Results are displayed in Figure 2. The number of 
particles per cell is linear with incubation dosage and undergoes 
exponential saturation with incubation time. In particular, after 
24 h, the effective rate of uptake per unit of incubation dosage 
is (580 ± 40) particles/cell/μM Au. In turn, with an incubation 
dosage of 400 × 10−6 m Au, the initial rate of uptake per unit 
of incubation time is (260 ± 50) particles/cell /min. In prac-
tice, macrophages treated for 24 h with 400 × 10−6 m Au con-
tain as many as ≈200 000 gold nanorods. These figures are in 
the same order of magnitude as the records that were reported 
by Vigderman et al.[58] when it is considered that macrophages 
are smaller than other kinds of cells. However, at variance with 
the use of particles without PEG, where the uptake of gold was 
found to vary from replica to replica by as much as a factor of 
≈3000%[44] under identical conditions, we verified that our pro-
tocol is reproducible within ±20%. This dramatic improvement 
is attributed to the colloidal stability that belongs to the steric 
hindrance of PEG. In addition, this hindrance persists even in 
the extreme densities of the endocytic vesicles, which is demon-
strated by the near-absence of plasmonic coupling in the spectra 
of optical extinction in Figure S2 of the Supporting Information.
2.3. Plasmonic Macrophages: Viability and Tropism
Perhaps, the most critical concern for the preparation of cel-
lular vehicles is about the preservation of their biological func-
tions of interest. Both the optical and the electron images of 
our macrophages reveal that their morphology remains normal 
upon interaction with polycationic gold nanorods, which points 
to an overall conservation of their physiology.
Figure 3a displays the viability of these cells upon incuba-
tion with cationic gold nanorods. A modest decrease is seen 
both with the incubation dosage and time, which is more likely 
to result from a reduction of cell proliferation rather than the 
onset of apoptosis or necrosis, according to our optical images. 
After incubation for 24 h with 400 × 10−6 m Au, the viability is 
still within ≈10% of control. Therefore we conclude that no sig-
nificant cytotoxic effect is detectible within the range of condi-
tions that was explored.
Figure 3b shows the migration of macrophages treated with 
100 × 10−6 and 400 × 10−6 m Au for 24 h with respect to con-
trols in the presence and absence of a chemotactic stimulus, 
such as a gradient of MIP-1α.[66] We emphasize that these cells 
were first prepared with polycationic gold nanorods and then 
tested for their chemotactic migration, as it would occur in a 
real-world application. Also this parameter keeps satisfactory.
Blank cells exhibit a very low level of motility in serum-free 
medium without chemokine. Likewise, the treatment with gold 
nanorods alone does not trigger their chemotaxis, thus dem-
onstrating that these particles are unable to activate murine 
macrophages. Conversely, their incubation with MIP-1α 
(50 ng mL−1) exerts a sharp increase in their chemotaxis. More 
than 90% of this migration is still observed in macrophages that 
were pretreated with 100 × 10−6 and 400 × 10−6 m Au and then 
exposed to MIP-1α. Therefore, our polycationic gold nanorods 
do not inhibit the chemotaxis of murine macrophages under 
these conditions.
These results are in line with those by Schnarr et al.[45] and 
Madsen et al.[38] and suggest that the chemotactic functions 
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Figure 1. a) (650 × 500) nm2 TEM image of assynthesized gold nanorods; 
b–d) (13 × 8.6) μm2, (2.3 × 1.7) μm2, and (870 × 650) nm2 TEM images 
of macrophages grown on polycarbonate membranes and treated for 24 h 
with polycationic gold nanorods at a concentration of 400 × 10−6 m Au. In 
panel (b), black and white dotted lines, respectively, denote plasmatic and 
nuclear membranes. For sample preparation, macrophages were fixed, 
and included in an epoxidic resin with their polycarbonate substrate. The 
appearance of the particles in panel (d) is affected by their inclination in 
the endocytic vesicles.
Figure 2. Number of polycationic gold nanorods that are taken up per 
macrophagic cell treated in a) for 24 h at different concentrations of gold 
and in b) for different incubation times with 100 × 10−6 (empty circles) 
and 400 × 10−6 m (full circles) Au. Data were retrieved from an optical 
analysis of aqueous suspensions of these cells and expressed as average ± 
standard deviation of three independent runs.
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of macrophages are robust in the presence of nontoxic gold 
nanoparticles.
Overall, our macrophages maintain well their viability and 
tropism in vitro, which is their principal functions in view of 
their use as Trojan horses.
2.4. Plasmonic Macrophages: Contrast for Biomedical Imaging
The possibility to map macrophagic infiltrates of cells treated 
with polycationic gold nanorods was addressed by PAI. These 
cells are tested as exogenous agents to enhance the optical 
contrast by their plasmonic cargo and to break through the 
imaging-depth limit. With this approach, the excitation of the 
plasmonic oscillations of gold nanorods with short optical 
pulses triggers a cascade of photothermal and thermoelastic 
conversion in their fluid environment, which leads to the emis-
sion of ultrasound.[7,8] Here, we combined a high resolution 
photoacoustic and micro-ultrasound platform that operates 
in the range of wavelengths between 680 and 970 nm and a 
linear array transducer. As for the samples, we used a tissue-
like optical phantom to achieve semiquantitative data from sets 
of microchannels drawn in a polymeric scaffold. Meanwhile, 
owing to the large atomic number of gold, we investigated the 
possibility to detect our macrophages with a microCT scanner.
The fingerprint of plasmonic macrophages was detected by 
the use of photoacoustic spectroscopy.[67,68] First, we recorded 
the photoacoustic signals from microchannels that were filled 
with aqueous suspensions of gold nanorods without cells. 
These data are reported in Figure S3 of the Supporting Infor-
mation and reveal that the plasmonic bands of these sam-
ples are retraced well down to concentrations in the range of 
≈100 × 10−6 m Au. The intensity of the photoacoustic signals 
undergoes exponential saturation with the dosage of gold, 
as the optical fluence becomes more and more exhausted by 
the particles, which was used to establish a calibration curve. 
Next, the microchannels were filled with ≈107 plasmonic mac-
rophages per cc. In this case, the shape of the photoacoustic 
spectra departs a little further from that of the optical extinc-
tion, which we ascribe to the onset of nonlinear effects, such 
as cavitation,[68,69] that grow up in the extreme densities of the 
endocytic vesicles.[70,71] Nonetheless, the intensity of the photoa-
coustic signals still scales with the number of particles per cell 
and fits rather well in the calibration curve, when the data from 
Figure 2 are worked out into the overall content of gold in these 
samples. All these data demonstrate that macrophages treated 
for 24 h with 100 × 10−6 to 400 × 10−6 m Au are discriminated 
well from a background of PBS even at a concentration of ≈1% 
(v/v), which is at least an order of magnitude below the typical 
fraction of the macrophagic infiltrate in a malignant lesion.
The same applies to whole blood as well. Figure 4a,b shows 
photoacoustic spectra and a representative photoacoustic image 
of three microchannels that were filled with human whole blood, 
a suspension of gold nanorods in whole blood at the concentra-
tion of 1 × 10−3 m Au and whole blood containing ≈3% (v/v) 
macrophages treated for 24 h with 400 × 10−6 m Au. The pho-
toacoustic spectra of whole blood display the typical fingerprint 
of oxygenated hemoglobin.[72,73] In addition to this fingerprint, 
the plasmonic band of gold nanorods dominates in both other 
samples and its intensity scales well with the concentration of 
gold, when it is considered that ≈3% (v/v) macrophages treated 
for 24 h with 400 × 10−6 m Au amounts to (2.3 ± 0.5) × 10−3 m Au. 
Figure 4a demonstrates that the detection limit of the plasmonic 
macrophages in whole blood falls well below 3% (v/v), which 
substantiates the feasibility of this approach in vivo.
In order to understand the possibility to image the accumu-
lation of these cells even deeper inside biotissue, we verified 
the contrast of gold nanorods by conventional CT from relevant 
inclusions of a volume of ≈100 μL. Figure S4 of the Supporting 
Information displays our calibration curve. At variance with the 
previous work by von Maltzahn et al.[17] we focused on a regime 
of lower concentrations of gold, which may be accessible by the 
use of cellular vehicles. In this regime, upon optimization of 
the setup, the absorbance is linear with the concentration of Au 
with a rate of (16 ± 2) H.U./mM Au.
Figure 4c displays a CT image of a set of inclusions con-
taining standard solutions of iodine in PBS, suspensions of 
gold nanorods in PBS at the concentration of 4 × 10−3 m Au, and 
≈8% (v/v) macrophages treated for 24 h with 400 × 10−6 m Au. 
We note that the latter is still well below the possible content 
of tumor-associated macrophages in a malignant lesion. There-
fore, the combination of Figure 4b,c illustrates the potential of 
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Figure 3. a) Viability of macrophagic cells treated for different incubation 
times with different concentrations of gold and retrieved from a WST-8 
assay. Data are expressed as percent of formazan with respect to controls. 
Values are reported as mean ± SD of three independent experiments; 
b) percent of macrophages treated for 24 h with different concentrations 
of gold that migrated after exposure to MIP-1α with respect to controls. 
The chemotaxis assay was performed by the use of Transwell permeable 
membranes. Results are shown as mean ± SD of three independent 
experiments.
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our cells as contrast agents for a multimodal approach of bio-
medical imaging.
In addition to their value for biomedical imaging, another 
major field of application for gold nanoparticles is the photo-
thermal ablation of cancer.[17,74–77] In this context, the same 
plasmonic oscillations of gold nanorods that provide for optical 
contrast for PAI are activated with a continuous wave in order 
to raise the temperature of their medium above the physiolog-
ical value. Figure S5 of the Supporting Information shows that, 
upon excitation with a continuous wave under conditions that 
are harmless to blank macrophages, those treated for 24 h with 
400 × 10−6 m Au undergo lethal damage within a few minutes. 
What is more, a monolayer of these cells is already sufficient 
to overheat their microenvironment above ≈65 °C (max contin-
uous service temperature of polystyrene), as it is inferred from 
their effect on the Petri dish. Therefore, in addition to their 
value as multimodal agents of contrast for biomedical imaging, 
these cells hold the potential to serve as microradiators for the 
photothermal ablation of cancer.
3. Conclusion
In conclusion, we have disclosed a new model of gold nanorods 
that combine strong cationic profiles and colloidal stability, by 
the development of a composite shell of quaternary ammonium 
compounds and PEG. These particles undergo efficient and 
reproducible uptake from tumor-tropic cells such as macro-
phages, which preserve their viability and more than 90% 
of their innate chemotactic behavior in vitro. The amount of 
particles per cell is fine-tunable with the parameters of their 
coincubation, at least until 200 000 gold nanorods per mac-
rophage. Under these conditions, these cells are detectible by 
PAI down to concentrations in the order of 1% in whole blood 
and by CT below 10%, which is well below the typical fraction 
of a leukocytic infiltrate in a tumor microenvironment. More-
over, these cells hold the potential to serve as contrast agents 
for the optical hyperthermia of cancer as well.
In the future, we will take the challenge to translate these 
results in vivo and to make a critical comparison with the con-
ventional approach to deliver plasmonic particles to tumors, 
which is their PEGylation, bioconjugation[20,24,30,31] and direct 
infusion into the bloodstream. Indeed, while tumor-tropic cells 
exhibit a unique ability to cross all biological barriers before 
their target much better than any artificial bullet, their actual 
biodistribution upon modification and reinjection into a full 
body remains an open question. In this context, we believe that 
the perspective to reproduce these results with complementary 
kinds of tumor-tropic cells, including T cells and stem cells, 
represents a remarkable opportunity.
4. Experimental Section
Preparation of Polycationic Gold Nanorods: Chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and used as received. The 
preparation of polycationic gold nanorods began with the synthesis of 
cetrimonium-capped gold nanorods by the autocatalytic reduction of 
chloroauric acid with ascorbic acid, according to our variant[78] of the 
method by Nikoobakht and El-Sayed.[79] These particles were purified by 
centrifugation and transferred at a concentration of 1.8 × 10−3 m Au into a 
100 × 10−3 m acetate buffer at pH 5 containing Cetyltrimethylammonium 
Bromide (CTAB, 500 × 10−6 m) and polysorbate 20 (50 ppm). In a typical 
run, an aliquot of this suspension (6 mL) was added with aqueous 
alpha-methoxy-omega-mercapto-PEG (MW ≈ 5000, 30 μL, 10 × 10−3 m), 
left to react for 30 min at 37 °C, added with MUTAB (30 μL, 100 × 10−3 m  
in dimethyl sulfoxide) and left at rest for another 24 h at 37 °C. 
Finally, these particles were purified by centrifugation and stored at a 
concentration of 4.5 × 10−3 m Au in sterile PBS at pH 7.4 until use.
Preparation of Plasmonic Macrophages: J774a.1 monocyte/macrophagic 
cells were purchased from the American Type Culture Collection (ATCC 
TIB-67, Manassas, VA, USA) and seeded on plastic culture dishes in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (10%), l-glutamine (1%), and a penicillin–streptomycin 
solution (1%) (BioWhittaker, Lonza, Visp, Switzerland). Cells were kept 
and left to grow under standard culture conditions (37 °C, 5% CO2).
In a typical run, an appropriate number of macrophages was cultured 
in complete medium for 24 h and then incubated in serum-free medium 
to maintain starvation. Appropriate aliquots of polycationic gold 
nanorods in PBS were diluted in serum-free medium, so as to achieve 
the final concentration of choice and left in incubation for the duration 
of choice.
Quantitative Measurement of Intracellular Uptake: The accumulation 
of gold nanorods in macrophages was quantified by an optical 
analysis.[24,63,64] 5 × 105 J774a.1 cells were plated in Petri dishes and 
treated with different concentrations of gold nanorods (4 × 10−6, 
10 × 10−6, 40 × 10−6, 100 × 10−6, and 400 × 10−6 m Au) for 24 h or 
with 100 × 10−6 and 400 × 10−6 m Au for different durations (0.5, 1, 2, 
4, 8, 16, and 24 h). Macrophages were harvested, thoroughly rinsed 
with PBS and fixed with paraformaldehyde (3.6% in PBS) for 10 min 
at room temperature. Then their pellets were washed, resuspended in 
PBS (120 μL), transferred into a quartz microcuvette and directed to an 
UV–NIR spectrophotometer (V-560, Jasco, Tokyo, Japan).
Measurement of Cellular Viability and Chemotaxis: Cellular viability 
was evaluated by a WST-8 assay (Cell counting kit-8, Sigma-Aldrich, 
St. Louis, MO, USA). The highly water-soluble tetrazolium salt WST-8 
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Figure 4. a) Photoacoustic spectra and b) (2.1 × 1.2) cm2 combined 
B-mode ultrasound (gray) and photoacoustic (red) image at an optical 
wavelength of 820 nm of three microchannels that were filled with human 
whole blood (1), a suspension of gold nanorods in whole blood at the 
concentration of 1 × 10−3 m Au (2) and whole blood containing ≈3% (v/v) 
macrophages treated for 24 h with 400 × 10−6 m Au (3). Note that samples 
are not in that order in panel (b); c) CT image of a set of inclusions con-
taining, from left to right, ≈8% (v/v) macrophagic cells treated for 24 h 
with 400 × 10−6 m Au, a suspension of gold nanorods at the concentration 
of 4 × 10−3 m Au, PBS and increasing dilutions of iodine in PBS (3.2 × 10−3, 
32 × 10−3, and 320 × 10−3 m I).
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is reduced by dehydrogenases within cells, which generates the yellow 
product formazan. The optical absorbance of formazan at 460 nm is 
proportional to the number of living cells. 8 × 103 macrophages were 
cultured in 96-well plates and incubated with 50 × 10−6, 100 × 10−6, 
200 × 10−6, and 400 × 10−6 m Au for 4, 24, and 48 h. Each sample was 
prepared in triplicate. At the end of the treatment, each well was washed 
with abundant PBS and cells were incubated with serum-free medium 
(100 μL) supplemented with WST-8 (10%) for 2 to 4 h at 37 °C. The 
optical absorbance of formazan was quantified by a microplate reader 
(LT-400, Labtech, Bergamo, Italy) at 460 nm with a reference at 630 nm. 
Data were expressed as the percentage of signal with respect to controls.
A migration assay was implemented by the use of 24-well plates with 
polycarbonate membrane inserts (8 μm pore size, Transwell Permeable 
Supports, Costar, Corning Life Sciences, Lowell, MA, USA). Confluent 
macrophages were incubated in serum-free medium and then treated 
with 100 × 10−6 and 400 × 10−6 m Au for 24 h. Thereafter 2.5 × 104 cells 
were harvested, resuspended in serum-free medium (100 μL) and 
added to the upper side of the inserts. The lower well was filled with 
serum-free medium (600 μL) with or without MIP-1α (50 ng mL−1) in 
the presence of bovine serum albumin (0.1%). These plates were left 
at 37 °C overnight. Thereafter non-migrated cells remaining on the 
upper side of the inserts were removed with a cotton swab. Migrated 
cells were fixed with paraformaldehyde (3.6% in PBS) for 10 min at room 
temperature and stained with Harris’ hematoxylin and eosin. Each insert 
was observed by a light microscope at 40× magnification and migrated 
cells were quantified as mean ± SD in five random fields.
Photoacoustic and CT Imaging: Photoacoustic measurements were 
performed with a photoacoustic system from VisualSonics Inc. (Vevo 
LAZR, VisualSonics Inc., Toronto, Canada) that produces photoacoustic 
images coregistered with B-mode ultrasound images. A full description 
of the system is available in the work of Needles et al.[73] Photoacoustic 
signals were excited by a pulsed (20 Hz repetition, 6 to 8 ns pulse 
duration) and tunable (680 to 970 nm wavelength) Nd:YAG laser-
pumped optical parametric oscillator through two rectangular fiber-optic 
bundles placed on both sides of a linear array transducer (13 to 24 MHz 
bandwidth, 23 mm × 30 mm field of view size) at an angle of 30° of 
the image plane. The acquisition time for a photoacoustic spectrum was 
about 60 s for 146 wavelength points.
A plastic device hosting six microchannels (μ-Slide VI0.1, Ibidi 
GmbH, Planegg, Germany) filled with different samples was used for 
photoacoustic measurements (Figure 5a). A 5 mm layer of tissue-like 
material composed of polydimethylsiloxane (PDMS) mixed with TiO2 
(0.73 mg mL−1) and India ink (0.25 mg mL−1) was deposited onto 
this device in order to gain more biomedical relevance and to prevent 
the gold nanorods to overheat upon irradiation.[80] A full description 
of the tissue-like material is reported elsewhere.[81] Spectra of optical 
absorbance were acquired from different dilutions of gold nanorods 
and different formulations of plasmonic macrophages that were either 
dispersed in PBS or in human whole blood.
In order to acquire CT scans, we used an IRIS scanner, which is a 
novel multimodal preclinical tomograph for high resolution positron 
emission tomography/CT imaging of small animals (Raytest, Inviscan 
Imaging System, Strasbourg, France). The CT section is equipped with 
a microfocus X-ray source (35 to 80 kV voltage, 80 W power) with fixed 
tungsten anode and nominal maximum focal spot size of 50 μm and with 
a flat-panel CMOS-based X-ray detector coupled to a CsI:Tl scintillator 
with a thickness of 150 μm. The detector is divided into 1536 × 
1944 square pixels (transaxial × longitudinal) with side length of 75 μm, 
for a total active surface of 115 mm × 145 mm. At full resolution, 
the minimum exposure time per frame in sequence mode is 39 ms, 
which can be shortened to 15 and 12 ms by 2 × 2 and 4 × 4 hardware 
rebinning, respectively. The nominal source-to-axis distance (SAD) and 
source-to-detector distance (SDD) are 206 and 262 mm, respectively, 
which results into a transaxial field of view diameter of 90 mm. Images 
are reconstructed by a Feldkamp-type filtered back-projection algorithm 
and calibrated in Hounsfield units (H.U.).
A 96-well plate containing different samples was used for CT 
measurements (Figure 5b). The optimization of the CT signal as a 
function of voltage was carried out with a clinical CT scan in the range of 
clinical relevance between 80 and 120 kV. Thereafter, 80 kV was chosen 
as the optimal voltage for CT acquisitions of samples containing gold 
nanorods by the IRIS scanner (80 μm voxel size, 1 mA current, 1280 n. 
of views, and ≈60 s acquisition time).
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